[{"id":"5b3f5b6d-e741-425a-9b64-0beca6fd42d7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03239392","created_at":"2021-01-18T16:00:27.423Z","updated_at":"2024-07-02T16:36:29.807Z","phase":"Phase 1/2","brief_title":"A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL","source_id_and_acronym":"NCT03239392","lead_sponsor":"Bioniz Therapeutics","biomarkers":" CD8 • B3GAT1","pipe":"","alterations":" ","tags":["CD8 • B3GAT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EQ101"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 04/01/2018","start_date":" 04/01/2018","primary_txt":" Primary completion: 06/30/2020","primary_completion_date":" 06/30/2020","study_txt":" Completion: 06/30/2020","study_completion_date":" 06/30/2020","last_update_posted":"2021-05-25"}]